Skip to main content
NASDAQ:FATE

Fate Therapeutics Competitors

$76.34
-0.36 (-0.47 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$73.62
$77.95
50-Day Range
$71.51
$92.52
52-Week Range
$27.64
$121.16
Volume963,623 shs
Average Volume1.05 million shs
Market Capitalization$7.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88

Competitors

Fate Therapeutics (NASDAQ:FATE) Vs. SGEN, TECH, ARGX, QGEN, NVAX, and RGEN

Should you be buying FATE stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Fate Therapeutics, including Seagen (SGEN), Bio-Techne (TECH), argenx (ARGX), QIAGEN (QGEN), Novavax (NVAX), and Repligen (RGEN).

Seagen (NASDAQ:SGEN) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

87.2% of Seagen shares are owned by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are owned by institutional investors. 31.1% of Seagen shares are owned by company insiders. Comparatively, 21.4% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Seagen and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Fate Therapeutics-810.13%-35.51%-25.40%

Risk & Volatility

Seagen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Earnings and Valuation

This table compares Seagen and Fate Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million29.29$-158,650,000.00($1.33)-111.26
Fate Therapeutics$10.68 million672.16$-98,150,000.00($1.44)-53.01

Fate Therapeutics has lower revenue, but higher earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Seagen and Fate Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen06912.69
Fate Therapeutics031102.79

Seagen currently has a consensus price target of $186.3571, suggesting a potential upside of 25.93%. Fate Therapeutics has a consensus price target of $110.4706, suggesting a potential upside of 44.71%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Seagen.

Summary

Seagen beats Fate Therapeutics on 8 of the 15 factors compared between the two stocks.

Bio-Techne (NASDAQ:TECH) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by company insiders. Comparatively, 21.4% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Bio-Techne and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
Fate Therapeutics-810.13%-35.51%-25.40%

Risk & Volatility

Bio-Techne has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bio-Techne and Fate Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million20.39$229.30 million$3.86100.35
Fate Therapeutics$10.68 million672.16$-98,150,000.00($1.44)-53.01

Bio-Techne has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Bio-Techne and Fate Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne03702.70
Fate Therapeutics031102.79

Bio-Techne currently has a consensus price target of $396.1111, suggesting a potential upside of 2.26%. Fate Therapeutics has a consensus price target of $110.4706, suggesting a potential upside of 44.71%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Bio-Techne.

argenx (NASDAQ:ARGX) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

54.2% of argenx shares are owned by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are owned by institutional investors. 21.4% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares argenx and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
argenxN/AN/AN/A
Fate Therapeutics-810.13%-35.51%-25.40%

Risk & Volatility

argenx has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Earnings and Valuation

This table compares argenx and Fate Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenx$78.17 million182.23$-182,520,000.00($4.73)-58.70
Fate Therapeutics$10.68 million672.16$-98,150,000.00($1.44)-53.01

Fate Therapeutics has lower revenue, but higher earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for argenx and Fate Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
argenx071002.59
Fate Therapeutics031102.79

argenx currently has a consensus price target of $300.7333, suggesting a potential upside of 8.32%. Fate Therapeutics has a consensus price target of $110.4706, suggesting a potential upside of 44.71%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than argenx.

Summary

Fate Therapeutics beats argenx on 10 of the 14 factors compared between the two stocks.

QIAGEN (NYSE:QGEN) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares QIAGEN and Fate Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.53 billion6.98$-41,460,000.00$1.4332.66
Fate Therapeutics$10.68 million672.16$-98,150,000.00($1.44)-53.01

QIAGEN has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for QIAGEN and Fate Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QIAGEN05902.64
Fate Therapeutics031102.79

QIAGEN currently has a consensus price target of $60.76, suggesting a potential upside of 30.11%. Fate Therapeutics has a consensus price target of $110.4706, suggesting a potential upside of 44.71%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than QIAGEN.

Risk & Volatility

QIAGEN has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Institutional and Insider Ownership

43.6% of QIAGEN shares are owned by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Comparatively, 21.4% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares QIAGEN and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QIAGEN11.18%17.51%8.44%
Fate Therapeutics-810.13%-35.51%-25.40%

Fate Therapeutics (NASDAQ:FATE) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Valuation and Earnings

This table compares Fate Therapeutics and Novavax's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$10.68 million672.16$-98,150,000.00($1.44)-53.01
Novavax$18.66 million556.54$-132,690,000.00($5.80)-24.17

Fate Therapeutics has higher earnings, but lower revenue than Novavax. Fate Therapeutics is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Fate Therapeutics and Novavax, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fate Therapeutics031102.79
Novavax11402.50

Fate Therapeutics currently has a consensus price target of $110.4706, suggesting a potential upside of 44.71%. Novavax has a consensus price target of $216.3333, suggesting a potential upside of 54.35%. Given Novavax's higher probable upside, analysts clearly believe Novavax is more favorable than Fate Therapeutics.

Volatility & Risk

Fate Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Institutional & Insider Ownership

99.7% of Fate Therapeutics shares are held by institutional investors. Comparatively, 49.9% of Novavax shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by company insiders. Comparatively, 3.3% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Fate Therapeutics and Novavax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fate Therapeutics-810.13%-35.51%-25.40%
Novavax-133.10%-1,346.17%-45.85%

Summary

Fate Therapeutics beats Novavax on 9 of the 14 factors compared between the two stocks.

Fate Therapeutics (NASDAQ:FATE) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Valuation and Earnings

This table compares Fate Therapeutics and Repligen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$10.68 million672.16$-98,150,000.00($1.44)-53.01
Repligen$270.24 million33.70$21.41 million$1.07155.02

Repligen has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Fate Therapeutics and Repligen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fate Therapeutics031102.79
Repligen00503.00

Fate Therapeutics currently has a consensus price target of $110.4706, suggesting a potential upside of 44.71%. Repligen has a consensus price target of $222.75, suggesting a potential upside of 34.29%. Given Fate Therapeutics' higher probable upside, research analysts clearly believe Fate Therapeutics is more favorable than Repligen.

Volatility & Risk

Fate Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

99.7% of Fate Therapeutics shares are held by institutional investors. Comparatively, 84.3% of Repligen shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by company insiders. Comparatively, 1.7% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Fate Therapeutics and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fate Therapeutics-810.13%-35.51%-25.40%
Repligen13.40%6.58%5.00%

Summary

Repligen beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks.

Ad Investing Trends
Elon Musk Picking Winners?
Lithium is Tesla’s life blood and China is strangling its supply. That’s why Elon Musk could be eying a Nevada lithium mine that’s just 188 miles from his Gigafactory – same day delivery!

Fate Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Seagen logo
SGEN
Seagen
1.5$147.98-0.3%$26.85 billion$916.71 million58.26Analyst Report
Bio-Techne logo
TECH
Bio-Techne
1.8$387.35-3.6%$15.06 billion$738.69 million61.98
argenx logo
ARGX
argenx
1.1$277.64-1.9%$14.24 billion$78.17 million-58.70Earnings Announcement
Analyst Downgrade
QIAGEN logo
QGEN
QIAGEN
1.7$46.70-0.2%$10.65 billion$1.53 billion57.65
Novavax logo
NVAX
Novavax
1.8$140.16-6.0%$10.39 billion$18.66 million-26.85Analyst Report
Repligen logo
RGEN
Repligen
1.9$165.87-3.7%$9.11 billion$270.24 million202.28
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.08-1.6%$8.80 billion$788.10 million100.09Analyst Downgrade
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$109.22-2.4%$8.28 billion$289.59 million-33.50
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$126.10-0.0%$7.65 billion$73.99 million-48.69Analyst Upgrade
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$53.64-0.5%$6.50 billion$26.68 million-24.27Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.7$42.42-1.4%$6.04 billion$195.99 million265.13Analyst Report
Vir Biotechnology logo
VIR
Vir Biotechnology
1.4$44.69-5.5%$5.81 billion$8.09 million-18.94
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$34.41-0.4%$4.83 billion$85.07 million-36.22
China Biologic Products logo
CBPO
China Biologic Products
0.8$119.99-1.7%$4.72 billion$503.70 million33.52Upcoming Earnings
Twist Bioscience logo
TWST
Twist Bioscience
1.6$93.71-1.1%$4.58 billion$90.10 million-24.99
Kodiak Sciences logo
KOD
Kodiak Sciences
1.7$84.60-0.7%$4.34 billionN/A-36.47Analyst Upgrade
News Coverage
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$69.15-4.0%$4.33 billion$20,000.00-4.92Analyst Report
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.9$26.49-2.5%$4.05 billionN/A-13.80Gap Down
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$28.60-3.8%$4.05 billionN/A-13.43
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$72.84-0.4%$3.57 billionN/A-41.86
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$30.35-3.8%$2.74 billionN/A0.00Earnings Announcement
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$14.38-10.7%$2.56 billion$48.83 million-18.92
Vericel logo
VCEL
Vericel
1.1$51.02-0.5%$2.37 billion$117.85 million-5,102,000.00Insider Selling
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.5$26.01-1.8%$2.32 billionN/A-12.15
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$31.48-1.6%$2.31 billion$50.04 million0.00Analyst Report
Editas Medicine logo
EDIT
Editas Medicine
1.6$33.11-0.3%$2.25 billion$20.53 million-19.03Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.7$49.20-0.2%$2.22 billion$125.57 million-28.77Analyst Report
News Coverage
bluebird bio logo
BLUE
bluebird bio
1.8$29.91-1.4%$2.02 billion$44.67 million-2.72
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.9$44.71-1.8%$2.01 billionN/A0.00
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.65-0.5%$1.91 billion$31.43 million-4.55
Ocugen logo
OCGN
Ocugen
1.0$8.60-1.7%$1.70 billionN/A-5.81
Replimune Group logo
REPL
Replimune Group
1.5$35.44-1.1%$1.65 billionN/A-20.02
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.89-0.4%$1.57 billion$102.43 million-18.15
AlloVir logo
ALVR
AlloVir
1.5$23.74-1.1%$1.55 billionN/A0.00
Immunovant logo
IMVT
Immunovant
1.6$15.50-0.0%$1.52 billionN/A-12.02Analyst Report
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$34.52-0.9%$1.49 billionN/A0.00Earnings Announcement
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$66.89-1.6%$1.49 billionN/A-45.20
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.74-4.0%$1.48 billion$35.23 million-14.01
Alector logo
ALEC
Alector
1.3$17.46-2.6%$1.39 billion$21.22 million-7.83
Curis logo
CRIS
Curis
1.1$15.05-9.8%$1.38 billion$10 million-18.35Earnings Announcement
Analyst Revision
Gap Down
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.26-1.9%$1.29 billion$100.56 million0.00Earnings Announcement
Translate Bio logo
TBIO
Translate Bio
1.6$17.00-0.9%$1.28 billion$7.80 million-15.89Analyst Report
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$14.37-4.3%$1.21 billionN/A-3.11
Cortexyme logo
CRTX
Cortexyme
1.1$38.68-4.9%$1.14 billionN/A-16.12
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.14-7.0%$1.07 billion$356.07 million6.93Analyst Report
News Coverage
Vaxcyte logo
PCVX
Vaxcyte
1.7$19.14-0.5%$983.39 millionN/A0.00Earnings Announcement
Scholar Rock logo
SRRK
Scholar Rock
1.5$28.41-1.7%$977.11 million$20.49 million-11.79Earnings Announcement
Mesoblast logo
MESO
Mesoblast
1.4$7.22-3.2%$936.72 million$32.16 million-8.20
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$19.79-0.6%$912.58 million$42.74 million-219.89
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.06-9.7%$906.22 millionN/A-4.14Unusual Options Activity
News Coverage
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.